Sol-Gel Technologies (NASDAQ:SLGL – Get Free Report) and Collegium Pharmaceutical (NASDAQ:COLL – Get Free Report) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, valuation, risk, analyst recommendations, earnings, dividends and institutional ownership.
Profitability
This table compares Sol-Gel Technologies and Collegium Pharmaceutical’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Sol-Gel Technologies | -910.14% | -44.05% | -36.96% |
| Collegium Pharmaceutical | 5.93% | 91.43% | 15.57% |
Volatility & Risk
Sol-Gel Technologies has a beta of 1.25, suggesting that its share price is 25% more volatile than the S&P 500. Comparatively, Collegium Pharmaceutical has a beta of 0.75, suggesting that its share price is 25% less volatile than the S&P 500.
Institutional & Insider Ownership
26.2% of Sol-Gel Technologies shares are held by institutional investors. 66.5% of Sol-Gel Technologies shares are held by insiders. Comparatively, 1.9% of Collegium Pharmaceutical shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
Analyst Recommendations
This is a summary of current recommendations for Sol-Gel Technologies and Collegium Pharmaceutical, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Sol-Gel Technologies | 1 | 0 | 4 | 2 | 3.00 |
| Collegium Pharmaceutical | 1 | 1 | 7 | 1 | 2.80 |
Sol-Gel Technologies currently has a consensus price target of $197.50, suggesting a potential upside of 224.09%. Collegium Pharmaceutical has a consensus price target of $44.88, suggesting a potential upside of 82.81%. Given Sol-Gel Technologies’ stronger consensus rating and higher probable upside, research analysts clearly believe Sol-Gel Technologies is more favorable than Collegium Pharmaceutical.
Valuation & Earnings
This table compares Sol-Gel Technologies and Collegium Pharmaceutical”s revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Sol-Gel Technologies | $19.39 million | 10.28 | -$6.13 million | ($5.64) | -10.80 |
| Collegium Pharmaceutical | $780.57 million | 1.02 | $62.87 million | $1.24 | 19.80 |
Collegium Pharmaceutical has higher revenue and earnings than Sol-Gel Technologies. Sol-Gel Technologies is trading at a lower price-to-earnings ratio than Collegium Pharmaceutical, indicating that it is currently the more affordable of the two stocks.
Summary
Collegium Pharmaceutical beats Sol-Gel Technologies on 8 of the 15 factors compared between the two stocks.
About Sol-Gel Technologies
Sol-Gel Technologies Ltd., together with its subsidiary Sol-Gel Technologies Inc., develops topical dermatological drugs for patients with severe skin conditions in Israel. The company offers Twyneo, a once-daily, non-antibiotic topical cream for the treatment of acne vulgaris; and Epsolay, a once-daily topical cream for the treatment of papulopustular (subtype II) rosacea. It also develops SGT-610 that is in Phase 3 clinical trials for the treatment of Gorlin Syndrome; and SGT-210, which has completed Phase I clinical trial, to treat rare hyperkeratinization disorders, such as Darier, PC, PPK, Olmsted, etc. In addition, the company is also involved in the development of generic topical dermatological drug products. It has collaboration with Padagis Israel Pharmaceuticals Ltd; and license agreements with Galderma Holding SA and Searchlight Pharma Inc. Sol-Gel Technologies Ltd. was incorporated in 1997 and is headquartered in Ness Ziona, Israel.
About Collegium Pharmaceutical
Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain. The company was formerly known as Collegium Pharmaceuticals, Inc. and changed its name to Collegium Pharmaceutical, Inc. in October 2003. Collegium Pharmaceutical, Inc. was incorporated in 2002 and is headquartered in Stoughton, Massachusetts.
Receive News & Ratings for Sol-Gel Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sol-Gel Technologies and related companies with MarketBeat.com's FREE daily email newsletter.
